Ubs Group Ag Sangamo Therapeutics, Inc Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Ubs Group Ag holds 1,249,009 shares of SGMO stock, worth $649,484. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,249,009
Previous 610,966
104.43%
Holding current value
$649,484
Previous $403,000
67.25%
% of portfolio
0.0%
Previous 0.0%
Shares
34 transactions
Others Institutions Holding SGMO
# of Institutions
125Shares Held
50.6MCall Options Held
1.1MPut Options Held
789K-
Vanguard Group Inc Valley Forge, PA9.37MShares$4.87 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT8.08MShares$4.2 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.84MShares$3.56 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$2.45 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$1.21 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $81.4M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...